eases. 1, 2 Following early speculation that blood may be a suitable source of cells for allogeneic transplantation, 3 preliminary results suggested that allogeneic blood cell transplantation was feasible, did not cause excessive acute graft-versus-host disease (GVHD), and hematologic reconstitution appeared to be faster than that seen after BM transplantation. [4] [5] [6] The numbers of nucleated cells, progenitor cells, and immunocompetent T cells contained in PBSC grafts are considerably higher than BM grafts in historical comparisons. 7, 8 No data are available comparing cell yields from PBSC and BM of the same individuals.
We undertook a double-blind, randomized study of PBSC vs BM for allogeneic transplantation to compare hematologic reconstitution, the incidence of GVHD and supportive therapy requirements. The aim of blinding the study was to eliminate the subjective element that invariably affects some parts of the management of allograft recipients such as diagnosis and grading of noncutaneous GVHD, supportive care, and discharge from the hospital. 9 As part of the study, each donor underwent a BM harvest followed by a granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC harvest. This report provides detailed analysis of cell yields and compares these two sources of hematopoietic stem cells.
Patients and methods
Between June 1995 and August 1997, 40 adult patients with hematologic malignancies and their HLA-identical sibling donors were enrolled into a double-blind, randomized study comparing PBSC and BM for allogeneic transplantation at the Royal Marsden Hospital in Surrey, UK. Thirty-nine patients were actually allografted. One patient developed fulminant disease recurrence after the donor was harvested. The study protocol, comprising harvest, transplantation, and donor preference assessment questionnaire, was approved by the institutional review board. The transplantation and donor preference issues are being addressed separately. 9 All patients and donors provided informed consent for the study.
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Study design
Donors underwent BM harvest under general anesthesia on day 1. The target cell count was 3 ϫ 10 8 total nucleated cells (TNC)/kg patient weight. Lenograstim (Granocyte; Chugai Pharma, London, UK) was administered at the single daily subcutaneous dose of 10 g/kg for 5 days starting from day 2, and a single leukapheresis performed on day 6 (the last day of the G-CSF). There was a provision for a second apheresis on day 7 if TNC collection from the first apheresis was Ͻ2 ϫ 10 8 /kg. BM was depleted of red cells and plasma by Ficoll separation prior to cryopreservation and flow cytometry irrespective of donor-recipient ABO incompatibility, 10 whereas PBSC were cryopreserved without any red cell or plasma depletion. Red cells separated from BM were reinfused to the donor.
Leukapheresis
In-dwelling vascular catheters were not inserted in any donor for harvesting stem cells, and large-bore peripheral venous cannulas were used. Leukapheresis was performed on a Cobe Spectra continuous flow cell separator (Cobe Laboratories, Lakewood, CO, USA) using the manufacturer's recommended technique. 11 The amount of blood processed was 10 liters or 200% of the donor's calculated total blood volume (the higher of the two) at a flow rate of 55-75 ml/min.
Investigations
For each BM and PBSC product, the following cell yield values were measured or calculated: TNC, automated differential count,
ϩ , and granulocyte-macrophage colony-forming units (CFU-GM).
Flow cytometry
All PBSC and BM samples were counted and used for flow cytometric analysis within 2 h of collection. The antibodies used were mouse anti-human CD45-FITC/CD14-RPE (Sigma, Poole, UK), CD25-RPE (Dako, Ely, UK), and CD3-FITC, CD4-PE, CD8-PE, CD16-PE, CD19-PE, CD33-PE, and CD34-FITC (all from Becton Dickinson, Cowley, UK).
Peripheral blood stem cell harvest samples were diluted 1 in 10 in phosphate-buffered saline before the addition of monoclonal antibodies. Aliquots of 50 l were dispensed into tubes of 5 l ready conjugated antibody agitated on a mixer and incubated at 4°C for 20 min. One ml of lysis solution (Ortho Diagnostics, Amersham, UK) was added to each tube and incubation continued at room temperature for 10 min. The tubes were transferred to an ice bath and analyzed immediately.
Samples were analyzed using dual fluorescence on an Ortho Cytoronabsolute (Ortho Diagnostics) flow cytometer with gating for lymphocytes. The absolute number of lymphocytes within the gate was determined from the number of cells expressing CD45. 10 000 events were counted for each sample. The machine was calibrated before use with normal donor blood that had been assessed for the differential count. Calibration for the lymphocyte gate ensured that Ͼ99% of the gated cells were lymphocytes. Data with experimental samples were collected in list mode file and analyzed using the software package supplied by the manufacturer. All subsequent calculations were based on the total white count assayed by a Coulter counter (Coulter Electronics Ltd, Luton, UK) to provide absolute counts of individual progenitor subsets.
The progenitor subsets assayed were CD34 ϩ /CD33 Ϫ and CD34 ϩ /CD33 ϩ . The CD34 ϩ cell subset results are derived by adding the two subsets that were assayed.
CFU-GM measurements
The CFU-GM assay was performed using a modification of the technique described by Pike and Robinson. 12, 13 The growth medium was the alpha modification of Eagle's minimal essential medium supplemented with 10% fetal calf serum, 1% bovine serum albumin, and 20 g/ml gentamicin. All cultures were done in 35-mm Petri dishes (Nunc, Roskilde, Denmark) to which 100 l of conditioned medium from the bladder carcinoma cell line 5637 was added as a source of growth factors. 5 ϫ 10 4 cells were plated per dish in quadruplicate as a single layer in 1 ml of growth medium containing 0.3% agar (Difco Noble; Difco, Detroit, MI, USA). Cultures were incubated for 14 days in a humidified atmosphere. The gas mixture to which cultures were exposed contained 5% CO 2 and 95% air. Colonies consisting of more than 50 cells were counted by lowpower inverted microscopy. The mean number of colonies from replicate dishes was used to calculate the CFU-GM yield from each harvest.
Statistical analysis
All values expressed per unit weight have been calculated on the basis of the patient as well as the donor weights. All statistical comparisons were performed using the Wilcoxon rank-sum test, and all P values shown are two-tailed. Regression analysis was employed to calculate the correlation between different cell populations.
Results
The median donor age was 37 years (range, 16-58) and the median weight 71 kg (range, 46-109). The median patient age was 37 years (range, 22-51) and the median weight 75 kg (range, 51-118). The median donor and patient weights were comparable, and the donor-patient weight disparity was not great at either extreme (heavier patient or heavier donor). The TNC target was met with a single apheresis in all the donors. Donor age had no effect on cell yields (data not shown).
Cell yields
As Table 1 shows, the proportion of CD34 ϩ cells and their subpopulations was higher in BM. Percent CD8 and CD16 cells were higher in BM, CD3, CD4 and CD19 cell proportions were comparable, and percent CD25 was higher in PBSC. However, since the TNC content of PBSC was considerably higher than marrow (Table 2) , CD34 ϩ cells and subpopulations, lymphocyte numbers and subsets, and CD16
ϩ and CD25 ϩ cell numbers were significantly higher in PBSC (Tables 2 and 3 ).
As Table 4 shows, the median yields from PBSC for all cell subsets were 2.2-to 9.3-fold higher than those from BM. There were two individual instances, one for CD16 cells and one for CD34 ϩ CD33 Ϫ cells, where the PBSC yield was less than the BM yield. Other than these two instances, PBSC yields were, at the minimum, 1.0-to 3.2-fold higher than those from BM. At the maximum, PBSC yields were 4.3-to 25.9-fold higher. Figures represent medians and ranges and are expressed per kg patient and donor weight separately. All comparisons are highly significant (P Ͻ 0.0001 for all except *P = 0.0003). Figures represent ratios of blood cell yields to marrow cell yields for individual donors/patients.
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Correlation between BM and PBSC
As Table 5 shows, there was no significant correlation between BM and PBSC TNC (Figure 1 ), CFU-GM, and CD16 ϩ cells. The correlation between BM and PBSC for CD34 ϩ cells (Figure 2 ), CD34 ϩ CD33 Ϫ cells, and CD19 ϩ 
Correlation between cell subsets within marrow and blood
The TNC number correlated well with CD34 ϩ cells, CFU-GM, CD3
ϩ cells, and CD4 ϩ cells in the BM and PBSC (data not shown). Its correlation with CD8 ϩ and CD19 ϩ cell numbers was good in PBSC but somewhat poor in BM. CD16 and CD25 subsets did not appear to correlate with any other subset in either BM or PBSC.
Blood cell yields in donors with 'poor' marrow yields
Thirty-five (88%) BM harvests contained Ͻ2 ϫ 10 6 CD34 ϩ cells/kg patient weight compared with five (13%) PBSC harvests (P Ͻ 0.0001). Thirty of the 35 donors (86%) who yielded Ͻ2 ϫ 10 6 CD34 ϩ cells/kg patient weight from BM had PBSC collections which contained у2 ϫ 10 6 CD34 ϩ cells/kg. On the contrary, none of the five donors yielding Ͻ2 ϫ 10 6 CD34 ϩ cells/kg patient weight from PBSC had yields of у2 ϫ 10 6 CD34 ϩ cells/kg from BM.
Discussion
Our data show that it is feasible to collect both BM and PBSC from a healthy donor 1 week apart. Despite a relatively high TNC target of 3 ϫ 10 8 /kg for BM harvests compared with one modest apheresis processing approximately 200% of the donor's calculated blood volume performed shortly after the BM harvest, the cell yields from PBSC are several times higher than those from BM. Depending upon the threshold dose of CD34 ϩ cells used (2 ϫ 10 6 CD34 ϩ cells/kg patient weight 14 ), a single apheresis is adequate to obtain a transplantable number of progenitor cells from 88% of the donors.
While the minimum threshold dose of CD34 ϩ cells for allogeneic transplantation has not been defined yet and it is possible that the threshold doses may be different for marrow and blood, we chose 2 ϫ 10 6 /kg because, in this study, 14 patients who received a lower number of progenitor cells than this had a significantly higher incidence of treatment-related mortality irrespective of whether they received marrow-or blood-derived cells.
TNC and CD34 ϩ cell yields from BM and PBSC correlated poorly in this study. Because of the significant effect TNC dose has on the outcome of allogeneic transplantation, [15] [16] [17] we aimed to collect 3 ϫ 10 8 TNC/kg from BM. CD34 ϩ cell measurement is likely to be a more precise measure of cell dose. If Ͻ2 ϫ 10 6 CD34 ϩ cells/kg is considered suboptimal, 14 88% of the BM harvests were inadequate. However, a single leukapheresis resulted in the collection of у2 ϫ 10 6 CD34 ϩ cells/kg in 88% including 30 of 35 (86%) of those with 'inadequate' marrow harvests. Thus PBSC proved to be a superior alternative in the majority of donors with suboptimal BM collections. This is a practically relevant observation.
Conversely, of the five donors whose PBSC contained Ͻ2 ϫ 10 6 CD34 ϩ cells/kg, none had BM harvests that contained у2 ϫ 10 6 CD34 ϩ cells/kg. This illustrates that BM is unlikely to be a superior substitute for PBSC, in terms of cell yields, under any circumstances. The volume of blood apheresed in this study was modest and only one apheresis was performed. With large-volume apheresis or multiple aphereses, as is commonly practised, the CD34 ϩ cell numbers from PBSC in the five donors with yields of Ͻ2 ϫ 10 ϩ , CD4 ϩ , CD8 ϩ and CD19 ϩ cell yields from PBSC were 4.6, 3.7, 16.1, 13.3, 27.4, and 11.0 times the corresponding populations from BM. It is interesting to note that the all subpopulation numbers from BM were very similar to ours with the exception of CD34 ϩ cell numbers which were considerably higher in the MD Anderson group. Despite this, the BM:PBSC CD34 ϩ cell ratios are comparable to our study (Table 5) while the other ratios are all higher. The major methodologic differences between the report of Körbling et al 7 and this study were as follows: the G-CSF dose (12 g/kg in two divided doses vs 10 g/kg in one dose), the day of starting apheresis (day 4 vs day 5), the number of aphereses (1-4 vs 1) , and the blood volume processed (300-700% vs 200-300%). 7 It is possible that these differences, while increasing the overall cell numbers 505 collected, result in a relatively higher collection of populations other than CD34 ϩ cells. Technical differences in the CD34 assay may also account for some of the difference.
In the Seattle comparison of BM and PBSC transplantation, 8 the median BM TNC dose was relatively lower at 2.07 ϫ 10 8 /kg and no BM subpopulation numbers were available. The PBSC numbers were slightly higher than those from the MD Anderson group. 7, 8 The Seattle group used a higher G-CSF dose (16 g/kg in two divided doses) and started apheresis on day 5.
While the differences between BM and PBSC composition and numbers certainly account for faster engraftment with PBSC, it is unknown what impact (if any) these would have on transplant-related mortality, relapse rates, longterm chronic GVHD, and long-term overall outcome 18 of transplantation. Our own preliminary observations indicate that relapse rates may be lower following PBSC transplantation. 19 Longer follow-up from controlled studies such as ours 9 and large series such as those from Seattle 8 and MD Anderson 7 will be able to address these issues. The study design was such that all donors gave BM before PBSC. It is possible that the preceding marrow collection with concomitant trauma and hemodynamic as well as hemopoietic stress affected the subsequent PBSC collection. However, we do not believe this affects the interpretation of the data obtained here. In clinical practice, donors are going to donate one or the other product and not both in tandem as they did in this study.
We conclude that the composition of BM and G-CSFmobilized PBSC harvests is significantly different, and cell subset numbers from PBSC are several-fold higher than from BM. It is possible to collect an adequate number of CD34 ϩ cells from the majority of donors with a single apheresis even when the harvest is performed shortly after a BM harvest. Donors whose BM progenitor cell yields are poor can still provide excellent PBSC numbers. It is likely that these dramatic differences in cell numbers underlie the clinical differences between allogeneic BM and PBSC transplantation.
